Abstract: Disclosed herein are virus-like particle (VLP)-based bivalent vaccine compositions. The compositions may comprise a spherical retroviral Group-specific Antigen (“Gag”) protein core and at least two Ebola glycoproteins. The at least two Ebola glycoproteins may be located at the exterior surface of the spherical Gag protein core, such that the VLP-based vaccine presents at least two Ebola glycoprotein antigens. In one aspect, the at least two Ebola glycoproteins are a Zaire (EBOV) glycoprotein, and a Sudan (SUDV) glycoprotein.

Abstract: Disclosed herein are virus-like particle (VLP)-based bivalent vaccine compositions. The compositions may comprise a spherical retroviral Group-specific Antigen (“Gag”) protein core and at least two Ebola glycoproteins. The at least two Ebola glycoproteins may be located at the exterior surface of the spherical Gag protein core, such that the VLP-based vaccine presents at least two Ebola glycoprotein antigens. In one aspect, the at least two Ebola glycoproteins are a Zaire (EBOV) glycoprotein, and a Sudan (SUDV) glycoprotein.

Abstract: Multiple cameras in a conference room, each pointed in a different direction and including a microphone array to perform sound source localization (SSL). The SSL is used in combination with the video image to identify the speaker from among multiple individuals that appear in the video image. Neural network or machine learning processing is performed on the identified speaker to determine the quality of the front or facial view of the speaker. The best view of the speaker's face from the various cameras is selected to be provided to the far end. If no view is satisfactory, a default view is selected and that is provided to the far end. The use of the SSL allows selection of the proper individual from a group of individuals in the conference room, so that only the speaker's head is analyzed for the best facial view and then framed for transmission.

Abstract: Multiple cameras in a conference room, each pointed in a different direction. At least a primary camera includes a microphone array to perform sound source localization (SSL). The SSL is used in combination with a video image to identify the speaker from among multiple individuals that appear in the video image. Neural network or machine learning processing is performed on the primary camera video of the identified speaker to determine the facial pose of speaker. The locations of the other cameras with respect to the primary camera have been determined. Using those locations and the facial pose, the camera with the best frontal view of the speaker is determined. That camera is set as the designated camera to provide video for transmission to the far end.

Abstract: Multiple cameras in a conference room, each pointed in a different direction and including a microphone array to perform sound source localization (SSL). The SSL is used in combination with the video image to identify the speaker from among multiple individuals that appear in the video image. Neural network or machine learning processing is performed on the identified speaker to determine the quality of the front or facial view of the speaker. The best view of the speaker's face from the various cameras is selected to be provided to the far end. If no view is satisfactory, a default view is selected and that is provided to the far end. The use of the SSL allows selection of the proper individual from a group of individuals in the conference room, so that only the speaker's head is analyzed for the best facial view and then framed for transmission.

Abstract: This disclosure relates to assays for detecting activating antibodies in a sample that are capable of antibody-dependent cell-mediated cytotoxicity. In certain embodiments, this disclosure relates to target cells comprising an antigen on the exterior of the cells and a luciferase inside the cells. In certain embodiments, the antigen is an Ebola-virus glycoprotein. In certain embodiments, this disclosure relates to detecting changes in chemiluminescence of the luciferase as an indication of activating antibodies in a sample capable of cell lysis when mixed with effector cells.

Abstract: Utilizing two LTR frames for improved error recovery. By using two LTR frames, much better performance is achieved in terms of error recovery as the likelihood of the decoder having one of the two LTR frames is very high. When the decoder determines a frame is lost, the decoder provides a fast update request (FUR). The FUR includes a listing of the LTR frames present at the decoder. With this indication of the LTR frames present at the decoder, the encoder utilizes one of the LTR frames, preferably the most recent, to use as a reference to send the next frame as a P frame. The P frame is sent with an indication of the LTR frame used as reference. The use of two LTR frames and the feedback of LTR frames present at the decoder allows the minimization of the use of I frames for error recovery.

Abstract: Disclosed herein are virus-like particle (VLP)-based bivalent vaccine compositions. The compositions may comprise a spherical retroviral Group-specific Antigen (“Gag”) protein core and at least two Ebola glycoproteins. The at least two Ebola glycoproteins may be located at the exterior surface of the spherical Gag protein core, such that the VLP-based vaccine presents at least two Ebola glycoprotein antigens. In one aspect, the at least two Ebola glycoproteins are a Zaire (EBOV) glycoprotein, and a Sudan (SUDV) glycoprotein.

Abstract: Disclosed herein are virus-like particle (VLP)-based bivalent vaccine compositions. The compositions may comprise a spherical retroviral Group—specific Antigen (“Gag”) protein core and at least two Ebola glycoproteins. The at least two Ebola glycoproteins may be located at the exterior surface of the spherical Gag protein core, such that the VLP-based vaccine presents at least two Ebola glycoprotein antigens. In one aspect, the at least two Ebola glycoproteins are a Zaire (EBOV) glycoprotein, and a Sudan (SUDV) glycoprotein.

Abstract: Utilizing two LTR frames for improved error recovery. By using two LTR frames, much better performance is achieved in terms of error recovery as the likelihood of the decoder having one of the two LTR frames is very high. When the decoder determines a frame is lost, the decoder provides a fast update request (FUR). The FUR includes a listing of the LTR frames present at the decoder. With this indication of the LTR frames present at the decoder, the encoder utilizes one of the LTR frames, preferably the most recent, to use as a reference to send the next frame as a P frame. The P frame is sent with an indication of the LTR frame used as reference. The use of two LTR frames and the feedback of LTR frames present at the decoder allows the minimization of the use of I frames for error recovery.

Abstract: Disclosed herein are virus-like particle (VLP)-based bivalent vaccine compositions. The compositions may comprise a spherical retroviral Group—specific Antigen (“Gag”) protein core and at least two Ebola glycoproteins. The at least two Ebola glycoproteins may be located at the exterior surface of the spherical Gag protein core, such that the VLP-based vaccine presents at least two Ebola glycoprotein antigens. In one aspect, the at least two Ebola glycoproteins are a Zaire (EBOV) glycoprotein, and a Sudan (SUDV) glycoprotein.

Abstract: Disclosed herein are virus-like particle (VLP)-based monovalent vaccine compositions. The compositions may comprise a spherical retroviral Group-specific Antigen (“Gag”) protein core and a single Ebola glycoprotein selected from either a Zaire (EBOV) glycoprotein or a Sudan (SUDV) glycoprotein. The Ebola glycoprotein may be incorporated into the surface of the spherical Gag core, wherein said VLP-based vaccine presents a single Ebola glycoprotein antigen.

Abstract: This disclosure relates to assays for detecting activating antibodies in a sample that are capable of antibody-dependent cell-mediated cytotoxicity. In certain embodiments, this disclosure relates to target cells comprising an antigen on the exterior of the cells and a luciferase inside the cells. In certain embodiments, the antigen is an Ebola-virus glycoprotein. In certain embodiments, this disclosure relates to detecting changes in chemiluminescence of the luciferase as an indication of activating antibodies in a sample capable of cell lysis when mixed with effector cells.

Abstract: Devices and techniques for overcoming lost packets and avoiding congestion when conducting media conferences over packet switched networks are described herein. To avoid the problem of lost packets, redundant information is inserted into the media stream that permits the receiver to reconstruct any lost packets from the redundant information. Congestion avoidance techniques include adjusting the bitrate of the media stream to find the highest bitrate that can be supported without packet loss due to congestion. When increasing the bitrate to a higher rate, the additional bits can come from the redundant information used for lost packet recovery so that any lost packets caused by network congestion will not adversely affect the bitstream.

Abstract: Devices and techniques for overcoming lost packets and avoiding congestion when conducting media conferences over packet switched networks are described herein. To avoid the problem of lost packets, redundant information is inserted into the media stream that permits the receiver to reconstruct any lost packets from the redundant information. Congestion avoidance techniques include adjusting the bitrate of the media stream to find the highest bitrate that can be supported without packet loss due to congestion. When increasing the bitrate to a higher rate, the additional bits can come from the redundant information used for lost packet recovery so that any lost packets caused by network congestion will not adversely affect the bitstream.

Abstract: Devices and techniques for overcoming lost packets and avoiding congestion when conducting media conferences over packet switched networks are described herein. To avoid the problem of lost packets, redundant information is inserted into the media stream that permits the receiver to reconstruct any lost packets from the redundant information. Congestion avoidance techniques include adjusting the bitrate of the media stream to find the highest bitrate that can be supported without packet loss due to congestion. When increasing the bitrate to a higher rate, the additional bits can come from the redundant information used for lost packet recovery so that any lost packets caused by network congestion will not adversely affect the bitstream.

Abstract: Devices and techniques for overcoming lost packets and avoiding congestion when conducting media conferences over packet switched networks are described herein. To avoid the problem of lost packets, redundant information is inserted into the media stream that permits the receiver to reconstruct any lost packets from the redundant information. Congestion avoidance techniques include adjusting the bitrate of the media stream to find the highest bitrate that can be supported without packet loss due to congestion. When increasing the bitrate to a higher rate, the additional bits can come from the redundant information used for lost packet recovery so that any lost packets caused by network congestion will not adversely affect the bitstream.

Abstract: The present invention provides for methods of identifying potential inhibitors of HIV infection and replication. More specifically, the invention identifies complexes between the ? subunit of AP-3 and Gag, which facilitate HIV assembly. Screening for inhibitors of this interaction will identify lead compounds for the treatment of HIV and AIDS.